OvaScience Announces Senior Management Changes and Appointments

31 Mar 2016, 00:00 AM EDT

– Arthur Tzianabos, Ph.D., Departs as President and Chief Scientific
Officer;
James D. Luterman, Ph.D., Appointed Senior Vice President,
Research & Development –

WALTHAM, Mass.–(BUSINESS WIRE)–OvaScience^SM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, today announced that Arthur Tzianabos, Ph.D., has
stepped down as President and Chief Scientific Officer to assume the
role of Chief Executive Officer at an early stage biotechnology company.
In order to facilitate an orderly transition, Dr. Tzianabos will consult
for the Company until the end of the year. James D. Luterman, Ph.D.,
OvaScience’s Vice President, Research & Development, has been appointed
the role of Senior Vice President, Research & Development and will
report directly to Michelle Dipp, M.D., Ph.D., Executive Chair and Chief
Executive Officer of OvaScience.

“We thank Arthur for his contributions to OvaScience that resulted in
the design and progression of three important treatments for women and
families facing infertility, including the AUGMENT treatment, which is
commercially available in select international regions,” said Michelle
Dipp, M.D., Ph.D., Executive Chair and Chief Executive Officer of
OvaScience. “Looking ahead, OvaScience is focused on building out our
commercial infrastructure to support the introduction of our treatments
to market. With the recent appointments of Chief Executive Officer-elect
Dr. Harald Stock and Chief Operating Officer Paul Chapman, we are well
positioned to support this effort and to expand patient access to our
important treatments.”

Dr. Dipp commented further, “We are pleased to recognize Jim’s strong
leadership with this appointment. He has played a fundamental role in
leading OvaScience’s research and development operations over the past
two years.”

James D. Luterman, Ph.D., has been with OvaScience since January 2014
and most recently has served as Vice President, Research & Development.
He brings over 20 years of industry experience to the Company. Prior to
OvaScience, Dr. Luterman served in various positions at Shire Human
Genetic Therapies, including Early Development Team Leader and Senior
Director Strategic Planning and Program Management. He also worked at
Biogen and Decision Resources Group. He holds a B.A. in Biology and
Psychology from Bucknell University and a Ph.D. in Behavioral and Neural
Sciences from Rutgers, the State University of New Jersey. Dr. Luterman
was a postdoctoral fellow at Mount Sinai School of Medicine.

About OvaScience
OvaScience (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for women
around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because we believe women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPC^SM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENT^SM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions. OvaScience has commenced a non-commercial
preceptorship training program with the OvaPrime^SM treatment,
which could increase a woman’s egg reserve, and is developing the OvaTure^SM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S. For more
information, please visit www.ovascience.com
and www.augmenttreatment.com
and connect with us on Twitter
and Facebook.

Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment, OvaPrime treatment and OvaTure treatment, including
statements relating to building out our commercial infrastructure and
expanding patient access to our treatments. Actual results may differ
materially from those indicated by these forward-looking statements as a
result of various important factors, including risks related to: the
possibility that international IVF clinics that we work with may
determine not to provide or continue providing the AUGMENT treatment or
OvaPrime treatment, or to delay providing such treatments based on
clinical efficacy, safety or commercial, logistic, regulatory or other
reasons; the science underlying our treatments (including the AUGMENT,
OvaPrime and OvaTure treatments), which is unproven; our ability to
obtain regulatory approval or licenses where necessary for our
treatments; our ability to develop our treatments on the timelines we
expect, if at all; our ability to commercialize our treatments, on the
timelines we expect, if at all; as well as those risks more fully
discussed in the “Risk Factors” section of our most recently filed
Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The
forward-looking statements contained in this press release reflect our
current views with respect to future events. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
in the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as representing our
view as of any date subsequent to the date hereof.